Hanall Biopharma Co., Ltd. (KRX:009420)
South Korea flag South Korea · Delayed Price · Currency is KRW
61,100
+300 (0.49%)
Feb 26, 2026, 11:20 AM KST

Hanall Biopharma Ratios and Metrics

Millions KRW. Fiscal year is Jan - Dec.
Fiscal Year
CurrentFY 2024FY 2023FY 2022FY 2021FY 2020
Period Ending
Feb '26 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20
3,087,4151,959,9522,245,705902,2901,077,8921,919,220
Market Cap Growth
47.95%-12.72%148.89%-16.29%-43.84%3.31%
Enterprise Value
3,076,8331,934,1972,185,410836,710991,8221,831,333
Last Close Price
60800.0038650.0044300.0017800.0021050.0037500.00
PE Ratio
1336.36-640.063588.03121.1697.10
Forward PE
389.58117.15261.09112.3065.1288.99
PS Ratio
20.0414.1116.658.2010.6121.66
PB Ratio
19.5811.6412.065.366.5910.59
P/TBV Ratio
32.1211.9612.185.436.6810.74
P/FCF Ratio
247.57253.9382.4740.22--
P/OCF Ratio
222.63209.4075.7635.711283.402065.25
PEG Ratio
-19.0919.0919.0919.0930.69
EV/Sales Ratio
19.9713.9216.207.619.7620.67
EV/EBITDA Ratio
-577.20437.93183.5577.34207.41
EV/EBIT Ratio
-8392.221253.51555.6698.21308.56
EV/FCF Ratio
246.72250.6080.2637.30--
Debt / Equity Ratio
0.010.010.010.010.010.00
Debt / EBITDA Ratio
0.180.430.260.290.100.06
Debt / FCF Ratio
0.110.190.050.06--
Net Debt / Equity Ratio
-0.07-0.14-0.30-0.31-0.48-0.50
Net Debt / EBITDA Ratio
-1.43-6.94-11.06-11.54-6.18-10.21
Net Debt / FCF Ratio
-0.85-3.01-2.03-2.3521.0455.21
Asset Turnover
0.740.610.600.530.490.43
Inventory Turnover
1.951.882.082.112.052.26
Quick Ratio
0.821.292.102.974.354.61
Current Ratio
2.012.463.023.925.375.61
Return on Equity (ROE)
1.40%-1.02%1.98%0.15%5.16%12.29%
Return on Assets (ROA)
1.16%0.06%0.48%0.46%3.02%1.80%
Return on Invested Capital (ROIC)
1.77%0.17%1.41%0.20%11.52%8.69%
Return on Capital Employed (ROCE)
2.30%0.10%0.90%0.80%5.70%3.00%
Earnings Yield
0.07%-0.09%0.16%0.03%0.83%1.03%
FCF Yield
0.40%0.39%1.21%2.49%-0.35%-0.08%
Buyback Yield / Dilution
-0.14%-0.04%0.24%0.76%-0.05%-0.00%
Updated Sep 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.